
Viscosafe CD 30mg/40mg Injection
Marketer
Intas Pharmaceuticals Ltd
Salt Composition
Sodium Hyaluronate (30mg) + Chondroitin (40mg)
Overview Viscosafe CD 30mg/40mg Injection
Arthrovis 30mg/40mg injection, a dual-action formulation, is indicated for osteoarthritis management. It alleviates pain and inflammation, thereby decreasing joint friction and improving mobility. Administration should always be performed by a healthcare professional; self-injection is strictly prohibited. Consistent daily dosing, at the same time each day, is crucial for optimal efficacy. Full therapeutic benefits may not be apparent immediately; a course of treatment is necessary. Discontinuation should only occur under medical supervision. Generally well-tolerated, minor injection site reactions (pain, redness, swelling) are possible. Report any adverse effects to your physician, who can advise on mitigation strategies. Prior to commencing therapy, disclose all pre-existing conditions and medications to your doctor to ensure safety and compatibility. Regular monitoring of kidney function and electrolyte levels may be required. Consult your physician before using this medication if you are pregnant or breastfeeding.
Uses of Viscosafe CD 30mg/40mg Injection
Managing Osteoarthritic Symptoms
Major Benefits of Viscosafe CD 30mg/40mg Injection:
This medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.
Common Side effects of Viscosafe CD 30mg/40mg Injection:
- Injection site reactions (pain, swelling, redness)
How to use Viscosafe CD 30mg/40mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
How Viscosafe CD 30mg/40mg Injection works:
Viscosafe CD Injection, containing 30mg of Sodium Hyaluronate and 40mg of Chondroitin, offers dual-action osteoarthritis relief. The hyaluronic acid salt, Sodium Hyaluronate, lubricates joints, promoting smoother movement. Chondroitin, a crucial cartilage component, acts as a dietary supplement to inhibit cartilage degradation and encourage its regeneration, preserving joint integrity.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Viscosafe CD 30mg/40mg Injection lacks established safety data. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Data on the administration of Viscosafe CD 30mg/40mg Injection to pregnant individuals is absent. Seek medical advice from your physician.
Breast feedingCONSULT YOUR DOCTOR
Data on Viscosafe CD 30mg/40mg Injection use while breastfeeding is lacking. Seek your physician's advice.
DrivingCONSULT YOUR DOCTOR
The impact of Viscosafe CD 30mg/40mg Injection on driving ability is undetermined. Refrain from driving if you experience symptoms impairing concentration or reaction time.
KidneyCONSULT YOUR DOCTOR
Insufficient data exists regarding Viscosafe CD 30mg/40mg Injection use in individuals with renal impairment. Physician consultation is advised.
LiverCONSULT YOUR DOCTOR
Insufficient data exists regarding the administration of Viscosafe CD 30mg/40mg Injection to individuals with hepatic impairment. Physician consultation is advised.
What if you forget to take Viscosafe CD 30mg/40mg Injection :
Omitting a scheduled dose of Viscosafe CD 30mg/40mg Injection necessitates contacting your physician.
Facts to Know About Viscosafe CD 30mg/40mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Pain Relievers |
